特发性肺纤维化市场规模、份额、成长分析，按药物类型、作用机制、最终用户和地区划分 - 产业预测，2024-2031

2022年全球特发性肺纤维化市场规模预估为35亿美元，预测期间（2024-2031年）复合年增长率为6.98%，从2023年的40.2亿美元增加至2031年的10.8亿美元。预计还会成长至十亿美元。

全球特发性肺纤维化（IPF）市场正在经历显着成长，这种严重肺部疾病的盛行率不断上升，其特征是进行进行性肺组织疤痕形成和功能障碍。这个市场的扩张主要归功于诊断技术的进步，这些技术增强了早期检测并实现了更好的疾病管理，以及医疗保健专业人员和患者对及时干预的必要性的认识不断提高。随着製药公司和研究人员专注于开发抗纤维化药物、免疫抑制剂和标靶治疗治疗等创新治疗方法，患者的治疗结果和生活品质得到了显着改善。然而，挑战依然存在，包括治疗成本上升、某些地区获得治疗方法的机会有限，以及需要继续研究以阐明 IPF 的复杂性。此外，美国IPF 市场预计未来将维持持续的复合年增长率，突显需要持续监测产业发展、新研究发现和监管更新。虽然这项见解凸显了 IPF 市场的成长和创新潜力，但它也认识到要充分满足患者需求并利用新兴治疗方法的优势必须克服的障碍。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 技术分析
• 管道分析
• 专利分析

特发性肺纤维化市场：依药物类型

• 市场概况
• 尼达尼布
• Pirfenidone
• 其他药物类型

特发性肺纤维化市场：按作用机制

• 市场概况
• 抗纤维化剂
• 蛋白酪氨酸激酶抑制剂
• 其他作用机制

特发性肺纤维化市场：依最终用户分类

• 市场概况
• 医院和诊所
• 药局
• 其他最终用户

特发性肺纤维化市场规模：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• United Therapeutics Corporation
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Cipla Inc.
• F. Hoffmann-La Roche Ltd
• FibroGen Inc.
• MediciNova Inc.
• Jubilant Pharma Limited（Jubilant Cadista Limited）
• Merck & Co. Inc.
• Horizon Therapeutics Inc.
• Avalyn Pharma Inc.
• AstraZeneca
• Novartis AG
• GlaxoSmithKline plc
• Genentech, Inc.
• Biogen Inc.
• Pfizer Inc.
• AbbVie Inc.
• Bayer AG
• Amgen Inc.

Global Idiopathic Pulmonary Fibrosis Market size was valued at USD 3.50 billion in 2022 and is poised to grow from USD 4.02 billion in 2023 to USD 10.80 billion by 2031, growing at a CAGR of 6.98% during the forecast period (2024-2031).

The global Idiopathic Pulmonary Fibrosis (IPF) market is experiencing significant growth, driven by the rising incidence of this serious lung condition characterized by progressive lung tissue scarring and functional impairment. This expansion is largely attributed to advancements in diagnostic technologies that enhance early detection and enable better disease management, alongside increased awareness among healthcare professionals and patients for the need for timely intervention. As pharmaceutical companies and researchers focus on developing innovative treatment modalities-such as antifibrotic agents, immunosuppressants, and targeted therapies-patient outcomes and quality of life are notably improving. Nonetheless, challenges such as high treatment costs, restricted access to therapies in certain areas, and the necessity for ongoing research to unravel the complexities of IPF persist. Furthermore, the U.S. IPF market is expected to maintain a sustainable compound annual growth rate (CAGR) in the upcoming years, highlighting the need for continuous monitoring of industry developments, new research findings, and regulatory updates. This insight emphasizes the potential for growth and innovation within the IPF market, while also acknowledging the obstacles that must be addressed to fully meet patient needs and harness the benefits of emerging therapies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Idiopathic Pulmonary Fibrosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Idiopathic Pulmonary Fibrosis Market Segmental Analysis

Global Idiopathic Pulmonary Fibrosis Market is segmented on the basis Global Idiopathic Pulmonary Fibrosis Market is segmented by Drug Type, Mode of Action, End User and Region. Based on Drug Type, the market is segmented into Nintedanib, Pirfenidone, Other Drug Types. Based on Mode of Action, the market is segmented into Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action. Based on End User, the market is segmented into Hospitals and Clinics, Pharmacies, Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Idiopathic Pulmonary Fibrosis Market

The Global Idiopathic Pulmonary Fibrosis (IPF) market is significantly propelled by relentless advancements in medical research and drug development aimed at unraveling the complex biology of IPF. This progress has led to the introduction of groundbreaking therapies, exemplified by antifibrotic agents such as Nintedanib and Pirfenidone, which have revolutionized treatment paradigms. These innovative options not only enhance survival rates but also markedly improve patients' quality of life, fueling patient demand and clinical adoption. As ongoing research continues to unveil new targets and treatment modalities, the market is poised for substantial growth, driven by a reinforced commitment to tackling this debilitating condition.

Restraints in the Global Idiopathic Pulmonary Fibrosis Market

One significant restraint in the Global Idiopathic Pulmonary Fibrosis (IPF) market is the prohibitive cost of treatment options. Medications like Nintedanib and Pirfenidone, while effective, are priced at a premium, limiting accessibility for patients, particularly in lower-income regions. This financial burden can deter patients from pursuing necessary therapies, resulting in diminished adherence to treatment regimens and compromised disease management. Furthermore, the escalating treatment costs can strain healthcare systems, raising concerns about disparities in access to effective care for all IPF patients, thereby hindering market growth and sustainability in various global territories.

Market Trends of the Global Idiopathic Pulmonary Fibrosis Market

A prominent trend in the Global Idiopathic Pulmonary Fibrosis (IPF) market is the growing emphasis on developing targeted therapies. Pharmaceutical companies and research institutions are directing resources toward innovative treatment modalities that specifically address the underlying mechanisms of IPF, offering a more personalized approach to patient care. This focus not only aims to enhance treatment efficacy but also seeks to mitigate side effects commonly associated with traditional therapies. As a result, targeted therapies are anticipated to revolutionize disease management, improving patient outcomes through tailored interventions. This trend signifies a paradigm shift towards precision medicine in the IPF landscape, reflecting the evolving needs of patients and healthcare systems worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Pipeline Analysis
• Patent Analysis

Idiopathic Pulmonary Fibrosis Market, By Drug Type

• Market Overview
• Nintedanib
• Pirfenidone
• Other Drug Types

Idiopathic Pulmonary Fibrosis Market, By Mode of Action

• Market Overview
• Antifibrotic Agents
• Tyrosine Kinase Inhibitors
• Other Modes of Action

Idiopathic Pulmonary Fibrosis Market, By End User

• Market Overview
• Hospitals and Clinics
• Pharmacies
• Other End Users

Idiopathic Pulmonary Fibrosis Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• United Therapeutics Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FibroGen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MediciNova Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Pharma Limited (Jubilant Cadista Limited)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avalyn Pharma Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments